论文部分内容阅读
目的研究艾迪注射液对晚期非小细胞肺癌GP方案化疗疗效及免疫功能的影响。方法选取非小细胞肺癌患者72例随机分为观察组和对照组。对照组患者给予GP方案化疗治疗。观察组患者给予艾迪注射液联合GP方案治疗。结果观察组近期总有效率与对照组比较无统计学差异(P>0.05)。治疗后,观察组患者整体生活质量、躯体功能、情绪功能、角色功能、认知功能、社会功能都高于对照组(均P<0.01),乏力、咳嗽、呼吸困难、胸痛都低于对照组(P<0.01或P<0.05)。治疗后,两组非小细胞肺癌患者免疫功能指标CD3+、CD3+CD4+、CD16+CD56+及CD4+/CD8+水平与治疗前相比均有所降低,但观察组患者均高于对照组(P均<0.01)。两组患者不良反应比较无统计学差异(P>0.05)。结论艾迪注射液联合GP方案治疗晚期非小细胞肺癌,能够促进化疗药物发挥良好抗癌功效,减轻化疗对患者生活质量及免疫功能损伤程度,且不增加化疗不良反应发生率。
Objective To study the effect of Aidi injection on the efficacy and immune function of GP regimen in advanced non-small cell lung cancer. Methods 72 patients with non-small cell lung cancer were randomly divided into observation group and control group. Patients in the control group received GP regimen chemotherapy. Patients in the observation group were given Aidi Injection combined with GP regimen. Results The total effective rate of the observation group compared with the control group had no statistical difference (P> 0.05). After treatment, the overall quality of life, body function, emotional function, role function, cognitive function and social function in the observation group were higher than those in the control group (all P <0.01), fatigue, cough, dyspnea and chest pain were lower than those in the control group (P <0.01 or P <0.05). After treatment, the immune function indexes of CD3 +, CD3 + CD4 +, CD16 + CD56 + and CD4 + / CD8 + in two groups of patients with non-small cell lung cancer were lower than those before treatment, but the patients in observation group were higher than those in control group (P < 0.01). Adverse reactions between the two groups showed no significant difference (P> 0.05). Conclusion Aidi injection combined with GP regimen in the treatment of advanced non-small cell lung cancer can promote chemotherapeutic drugs to exert good anticancer efficacy, reduce the quality of life and immune function damage of chemotherapy, and does not increase the incidence of adverse reactions.